Petaran

Petaran: Versatile Monophasic HA Filler for Balanced Correction from Superficial Radiance to Moderate Volume

Petaran , manufactured by **Hugel Inc.** (South Korea), is a **monophasic, non-animal stabilized hyaluronic acid (NASHA) dermal filler** designed for **balanced versatility**, effectively addressing indications from superficial skin quality enhancement to moderate volumization. Presented in a **1.0 ml prefilled syringe**, it contains a **moderate-to-high concentration (23 mg/ml) of cross-linked HA**. While **no lidocaine is integrated**, its adaptable gel properties and injection techniques allow for comfortable use with appropriate adjunctive anesthesia. Petaran’s key strength lies in its **homogeneous gel structure** engineered for smooth tissue integration and predictable flow across different depths.https://skin-reboot.com/

Petaran

**Core Technology & Properties:**
* **Monophasic NASHA Gel:** Features a uniform, BDDE-cross-linked HA matrix (Crystal Matrix Technology™), ensuring excellent cohesion, stability, and biocompatibility. This structure minimizes the risk of clumping and promotes even distribution.
* **Adjustable G-Prime Profile:** Exhibits **variable elasticity** based on injection technique and depth. It behaves as a **medium G-prime** filler for volumizing mid-to-deep layers (e.g., cheeks, NLFs) and transitions towards a **lower G-prime** character for superficial fine lines and skin hydration when placed subtly.
* **High Cohesivity:** Particles bind cohesively, providing structural integrity, minimizing migration risk, and allowing for smooth layering or threading.
* **Optimized Viscosity & Spreadability:** Designed for ease of injection through needles and cannulas, facilitating techniques like linear threading, fanning, and bolus placement depending on the target layer and indication.
* **Fine Particle Size:** Enhances suitability for superficial placement without significant Tyndall risk when injected correctly.

**Mechanism of Action:**
1. **Volumization:** Restores lost volume in mid-to-deep dermal/subcutaneous layers.
2. **Fold & Line Correction:** Fills moderate nasolabial folds, marionette lines, and superficial fine lines.
3. **Hydration & Radiance:** HA binds water, improving skin hydration, elasticity, and surface luminosity, especially with superficial micro-droplet technique.
4. **Biostimulation:** Provides a scaffold for potential collagen and elastin production over time.
5. **Contouring:** Enhances facial contours like cheeks, chin, and jawline.

**Primary Indications:**
* **Nasolabial Folds (Mild to Moderate):** Primary indication for fold effacement.
* **Marionette Lines & Pre-jowl Sulcus:** Correcting oral commissure descent and pre-jowl hollowing.
* **Cheek Augmentation & Volumization (Moderate):** Restoring midface volume and contour.
* **Lip Enhancement (Body & Border):** Adding volume and defining vermilion border (requires technique precision).
* **Fine Lines & Skin Quality Improvement:** Superficial injection for hydration and radiance (e.g., perioral, periorbital, décolletage – micro-droplet technique).
* **Chin & Jawline Definition:** Enhancing projection and contour.
* **Dorsal Hand Rejuvenation:** Correcting volume loss.

**Key Administration Considerations:**
* **Ready-to-Use:** No reconstitution required.
* **Anesthesia:** **Essential adjunctive anesthesia required** (topical, local infiltration, blocks). No integrated lidocaine.
* **Technique:** Highly versatile:
* **Needles:** Suitable for sharp needles (27-30G for superficial, 25-27G for deeper).
* **Cannulas:** Compatible with blunt cannulas (25-27G) for safer placement in sensitive areas (lips, NLFs).
* **Methods:** Linear threading, fanning, serial puncture, micro-droplet (superficial), bolus (deeper).
* **Depth:** **Adaptable:** Superficial dermis (micro-droplet for skin quality), mid-to-deep dermis (folds, lips), subcutaneous (volumizing cheeks/chin). *Critical to match depth to indication.*
* **Volume:** Moderate volumes. Gradual layering recommended.
* **Post-Treatment:** Swelling, redness, tenderness, bruising possible. Avoid pressure.
* **Longevity:** Typically **9-12 months**, varying with indication and depth.
* **Safety:** **Critical Risks:** **Vascular occlusion** (especially lips/NLF area – requires aspiration if needle used, cannula preferred). **Tyndall effect** if injected too superficially in certain areas. Risk of **nodules/lumps** with poor technique or overcorrection. Granuloma risk (rare). Lidocaine allergy irrelevant.
* **Regulatory Status:** **CE marked** (Europe/international). **Not FDA-approved in the USA.**
* **Prescription:** Prescription medical device.

Petaran offers injectors a flexible monophasic HA solution for a wide range of facial rejuvenation goals, from subtle superficial radiance to structured moderate volumization, demanding careful technique selection based on the target layer.CONTACT US